-
Published 5/21/2025
Baka T, Moore J, Qin F, Yurista SR, Zhang A, He H, Chambers JM, Croteau D, Goel RK, Smith H, Wang MC, Chen CS, Hobai IA, Rombaldova M, Kuda O, Tardiff JC, Balschi JA, Pimentel DR, Seidman CE, Seidman JG, Emili A, Colucci WS, Luptak I. Empagliflozin enhances metabolic efficiency and improves left ventricular hypertrophy in a hypertrophic cardiomyopathy mouse model. Eur Heart J. 2025 May 21. PMID: 40396194.
-
Published 4/9/2025
Chambers JM, Croteau D, Pimentel DR, Gower AC, Panagia M, Baka T, Qin F, Luptak I, Colucci WS. SGLT2 inhibitor upregulates myocardial genes for oxidative phosphorylation and fatty acid metabolism in Gaq-mice. J Mol Cell Cardiol Plus. 2025 Jun; 12:100296. PMID: 40291834.
-
Published 3/26/2025
Valero-Muñoz M, Saw EL, Cooper H, Pimentel DR, Sam F. White Adipose Tissue in Obesity-Associated HFpEF: Insights From Mice and Humans. JACC Basic Transl Sci. 2025 Mar 26. PMID: 40338771.
-
Published 6/13/2023
Rucker DM, Siddiqi OK, Pimentel DR, Luptak I. Hemodynamic testing to guide vasodilator therapy in cardiac amyloidosis. J Cardiol Cases. 2023 Sep; 28(3):105-108. PMID: 37671260.
-
Published 1/31/2023
Croteau D, Baka T, Young S, He H, Chambers JM, Qin F, Panagia M, Pimentel DR, Balschi JA, Colucci WS, Luptak I. SGLT2 inhibitor ertugliflozin decreases elevated intracellular sodium, and improves energetics and contractile function in diabetic cardiomyopathy. Biomed Pharmacother. 2023 Apr; 160:114310. PMID: 36731341.